Literature DB >> 18505048

Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer.

Hanna Dahlstrand1, Anders Näsman, Mircea Romanitan, David Lindquist, Torbjörn Ramqvist, Tina Dalianis.   

Abstract

The aim of this review is to present the current knowledge on the status and significance of human papillomavirus (HPV) in tonsillar cancer. An increase in the incidence of tonsillar cancer has been reported and recent data suggest that this increase is due to an increased proportion of HPV in these tumours. Furthermore, patients with HPV positive cancer have been shown to have a lower risk of relapse and longer survival compared to patients with HPV-negative tonsillar cancer. Tailoring individual treatment in tonsillar cancer may be of importance in order to reduce patient suffering as well as to increase patient survival. Finally, the fact that the presence of HPV-type 16 E6 and E7 mRNA has been ascertained in tonsillar cancer suggests that HPV-16 indeed is an aetiological factor associated with the disease and that preventive vaccination for this patient group should be discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18505048

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

Review 1.  Vaccination against human papilloma virus (HPV): epidemiological evidence of HPV in non-genital cancers.

Authors:  Ioannis N Mammas; George Sourvinos; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2010-07-18       Impact factor: 3.201

2.  Differential biomarker expression in head and neck cancer correlates with anatomical localization.

Authors:  László Tamás; Gabriella Szentkúti; Mónika Eros; Kornél Dános; Diána Brauswetter; Béla Szende; Ivett Zsákovics; Tibor Krenács
Journal:  Pathol Oncol Res       Date:  2011-04-13       Impact factor: 3.201

3.  The role of chemotherapy in the management of patients with head and neck cancer.

Authors:  Panayiotis Panos Savvides
Journal:  Semin Plast Surg       Date:  2010-05       Impact factor: 2.314

Review 4.  p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma.

Authors:  James S Lewis
Journal:  Head Neck Pathol       Date:  2012-07-03

5.  Discrimination of 'driver' and 'passenger' HPV in tonsillar carcinomas by the polymerase chain reaction, chromogenic in situ hybridization, and p16(INK4a) immunohistochemistry.

Authors:  Mark Francis Evans; Alisa Matthews; Dina Kandil; Christine Stewart-Crawford Adamson; Winifred Elizabeth Trotman; Kumarasen Cooper
Journal:  Head Neck Pathol       Date:  2011-07-24

6.  No role for human papillomavirus in esophageal squamous cell carcinoma in China.

Authors:  Jill Koshiol; Wen-Qiang Wei; Aimee R Kreimer; Wen Chen; Patti Gravitt; Jian-Song Ren; Christian C Abnet; Jian-Bing Wang; Farin Kamangar; Dong-Mei Lin; Magnus von Knebel-Doeberitz; Yu Zhang; Raphael Viscidi; Guo-Qing Wang; Maura L Gillison; Mark J Roth; Zhi-Wei Dong; Esther Kim; Philip R Taylor; You-Lin Qiao; Sanford M Dawsey
Journal:  Int J Cancer       Date:  2010-07-01       Impact factor: 7.396

7.  The clinical impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and neck squamous cell carcinomas.

Authors:  Jens Jakscha; Inti Zlobec; Claudio Storck; Ellen C Obermann; Luigi Tornillo; Luigi M Terracciano; Claude A Fischer
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-05-16       Impact factor: 2.503

Review 8.  Immune suppression in head and neck cancers: a review.

Authors:  Anaëlle Duray; Stéphanie Demoulin; Pascale Hubert; Philippe Delvenne; Sven Saussez
Journal:  Clin Dev Immunol       Date:  2011-03-10

9.  Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status.

Authors:  Malin Wendt; Lalle Hammarstedt-Nordenvall; Mark Zupancic; Signe Friesland; David Landin; Eva Munck-Wikland; Tina Dalianis; Anders Näsman; Linda Marklund
Journal:  Cancers (Basel)       Date:  2021-05-23       Impact factor: 6.639

10.  Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations.

Authors:  Stefan Holzhauser; Nicole Wild; Mark Zupancic; Ramona G Ursu; Cinzia Bersani; Anders Näsman; Ourania N Kostopoulou; Tina Dalianis
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.